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Background: Gastroschisis, a congenital anomaly of the abdomen, is associated with young 
maternal age and has increased in prevalence in many countries.  Maternal illness and 
medication exposure are among environmental risk factors implicated in its aetiology. 
Methods: A population-based case-malformed control study was conducted using data from 
18 European congenital anomaly registries, with information on first trimester medication 
use, covering 8 million births 1995-2012.  1,577 gastroschisis cases (of which 4% stillbirths, 
11% terminations of pregnancy) were compared to 153,357 non-chromosomal/monogenic 
controls.  Literature review identified previous associations concerning maternal illness and 
medication exposure to be tested as signals. Logistic regression adjusted for maternal age 
group, registry and time period was used to evaluate associations. 
Results: Comparing gastroschisis to other congenital anomalies, the data supported signals 
concerning maternal depression [aOR 2.52, 95% CI 1.45, 4.39], antidepressant use [aOR 
2.03, 95% CI 1.22, 3.38], postnatal depression/psychosis following a previous pregnancy 
[aOR 8.32, 95% CI 2.56, 27.01], sexually transmitted infections [aOR 2.85, 95% CI 1.13, 
7.24], topical antivirals [aOR 5.31, 95% CI 1.63, 17.33] and continuation of oral 
contraceptives in early pregnancy [aOR 2.17, 95% CI 1.13, 4.18]. Exploratory analyses 
suggested associations with a wider range of maternal infections and medications, including 
tonsillitis and the expectorant bromhexine.  
Conclusions: While it is difficult to disentangle the effects of the medication and underlying 
indication, our results add to the evidence base on preventable risk factors for gastroschisis. 
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These risk factors may contribute to the higher risk among young mothers, and geographical 
and temporal variation in prevalence.   
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Gastroschisis in Europe– A Case-malformed Control Study of Medication and 




Gastroschisis is a congenital anomaly where the small intestine, part of the large 
intestine and occasionally other abdominal organs protrude through a lateral defect in the 
ventral abdomen.1,2 The majority of cases are isolated anomalies.3 The pathogenesis of 
gastroschisis is uncertain but it is thought to occur between the third and eighth gestational 
weeks. Historically a vascular disruption mechanism was proposed but recent hypotheses 
focus on abnormalities in the process of body wall4 or umbilical ring1 development.  
 
Young maternal age has consistently been associated with an increased risk of 
gastroschisis.5,6 Links have also been found with nulliparity,7 white, Hispanic and indigenous 
Australian ethnic groups,7,8 smoking,9 alcohol,10 illicit drug use,11 medication exposure,9,12 
maternal illness13 and low pre-pregnancy body mass index.14  None of these factors have 
been found to explain the geographical variation in prevalence in Europe,5 or the increase in 
prevalence seen since the 1970s.7,15 
 
EUROmediCAT is a population based reproductive pharmacovigilance system, based 
on the European Surveillance of Congenital Anomalies (EUROCAT) network, and provides 
an opportunity to undertake research on medication exposure and maternal illness.16,17 This 
study aimed to use the EUROmediCAT database to test signals from the literature concerning 






A case-malformed control study was conducted using the EUROmediCAT database.  
Cases of gastroschisis were compared to controls with other non-chromosomal/monogenic 
congenital anomalies. The case-malformed control methodology was initially proposed for 
birth defect epidemiology as a method of controlling for maternal recall bias.18,19 It is used in 
EUROmediCAT to control for the source of exposure data and because data on non-
malformed controls are not available.20  
 
Study population and data 
 
EUROCAT registries record all cases of major congenital anomalies among live 
births, fetal deaths ≥20 weeks’ gestation and termination of pregnancy for fetal anomaly 
(TOPFA), in their populations using International Classification of Diseases (ICD)-9/ICD-10-
British Paediatric Association (BPA) codes.16 The EUROmediCAT database includes data, 
from 1995, from those EUROCAT registries that record first trimester medication exposure 
either directly or through linkage with healthcare databases.21 Eighteen EUROmediCAT 




Table 1. Total births in population, number of Gastroschisis cases, number of malfromed controls, and total prevalence of Gastroschisis 
per 10,000 births by EUROCAT Registry, 1995-2012 
Country Registry Time period 








per 10,000 births 
[95% Confidence 
Interval] 
Belgium Antwerp 1997-2012 308,067 43 6,510 1.4 [1.0, 1.9] 
Croatia Zagreb 1995-2012 120,403 21 1,858 1.7 [1.1, 2.7] 




2002-2012 161,071 37 3,530 2.3 [1.6, 3.2] 
France Paris 2001-2012 319,636 51 7,608 1.6 [1.2, 2.1] 














1995-2012 595,214 52 9,923 0.9 [0.7, 1.1] 





1995-2012 340,310 38 7,373 1.1 [0.8, 1.5] 
Norway Norway 2005-2010 364,160 116 9,249 3.2 [2.6, 3.8] 













Vaud 1997-2012 120,397 18 3,729 1.5 [0.9, 2.4] 
Ukraine Ukraine 2005-2012 241,508 86 5,219 3.6 [2.8, 4.4] 
United 
Kingdom 
Wales 1998-2012 501,720 278 16,220 5.5 [4.9, 6.2] 
Total 1995-2012 8,096,594 1,587b 154,877 2.0 [1.9, 2.1] 
a Total cases = (Live births + stillbirths+ terminations of pregnancy). Excludes those with a chromosomal/monogenic syndrome 
b Ten gastroschisis cases were excluded from the case-malformed control analysis as they were also recorded as having omphalocele, non-specific abdominal wall anomalies, limb-body-wall 




Cases and controls 
 
Gastroschisis cases were those with an ICD-9 with BPA extension code 75671 or ICD-
10 code Q793.  Malformed controls consisted of those with a diagnosis of a major congenital 
anomaly not including gastroschisis. Those with codes for omphalocele (ICD-9-BPA 75670 
or ICD-10 code Q792), non-specific abdominal wall anomalies (ICD-9-BPA 75679), limb-
body-wall complex (ICD-10 Q795) or body stalk anomalies were excluded from both cases 
and controls.16  Chromosomal/monogenic conditions were excluded from cases and controls. 





First trimester maternal medication exposures were mostly obtained by registries from 
prospectively recorded maternity records.  Additional data sources included the medical 
records of the infant, general practitioner records, maternity passports, and maternal 
interviews before or after birth.17 Norway medication exposures were based on first trimester 
prescription redemption records.  Emilia Romagna did not have medication information for 
TOPFA.  All first trimester medication exposures were recorded using the World Health 
Organization Anatomical Therapeutic Chemical (ATC) classification system. This is a 
hierarchical system which categorizes substances according to the organ or system on which 
they act (1st level) and their therapeutic (2nd level), pharmacological (3rd level) and 
chemical properties (4th and 5th level).  First trimester was defined as the period from the 
first day of the last menstrual period to the end of gestational week 12.  Medications taken in 




Maternal illnesses before pregnancy, which may affect fetal development, and illnesses 
occurring during the first 20 weeks of pregnancy were recorded, mostly prospectively from 
maternity records, using ICD-9/ICD-10 codes.16  Registries not recording maternal illness 
were excluded from this analysis. In Norway, data were limited to maternal pregestational 
diabetes, asthma, epilepsy and pre-eclampsia so data from this registry were excluded from 
all other maternal illness analyses.  See Supporting Figure 1 for the number of fetuses 
involved at each stage.  
 
Literature review to identify signals  
 
A literature review was conducted to identify all first trimester medication exposures or 
maternal illnesses that were previously reported to be associated with gastroschisis. Medline, 
Embase and PubMed were searched, with no date or language limits. The search, detailed in 
Supporting Appendix 1 and Supporting Figures 2 and 3, was last updated on the 13/11/2015. 
Supporting Tables 1 and 2 report the positive associations, or signals, identified by individual 
studies.  
 
Seventeen case-control studies and one cohort study reported associations between 
gastroschisis and 20 medications/medication groups.  Seven case-control and 2 cohort studies 
reported associations between gastroschisis and 19 maternal illnesses/groups of illnesses. A 
number of reported associations were not explored due to insufficient exposures in the 






All analyses were conducted in Stata/SE 12.1 (StataCorp LP, USA).  Prevalence rates, 
per 10,000 births were calculated as the (number of cases (Live Births + Still Births + 
TOPFA)/the number of births (Live Births + Still Births)) x 10,000.  
 
Odds Ratios (ORs) were calculated for each of the medication exposure and maternal 
illness signals described in the literature where there were at least 3 observed, or 3 expected, 
gastroschisis cases in the EUROmediCAT database.  If the signal was at the higher level, 
component groups were considered ‘signal components’ and are indicated as such in the 
tables e.g. depression was considered a component of the ‘any mental disorder’ signal. In 
addition, all medication exposures at the 5th and 4th ATC level and maternal illness, before 
or during pregnancy, with at least 3 observed, or 3 expected, gastroschisis cases were 
included in an exploratory signal generating analysis. If the same number of gastroschisis 
cases were exposed at the 4th and 5th level, the 4th level exposure was not investigated.  
 
Logistic regression was used to calculate crude and adjusted ORs, and 95% CIs, for 
each exposure.  Adjustment was made for maternal age group (<20, 20-24, 25-29 and 30+), 
registry and time period (1995-2000, 2001-2006 and 2007-2012).  Likelihood ratio tests were 
used to assess interactions between maternal age and exposure variables.   
 
For the medication exposures, sensitivity analyses were conducted 1) excluding those 
with pregestational or gestational diabetes, antidiabetic or anti-epileptic medication 2) 
excluding those whose medication exposure status was ‘unknown’ 3) excluding those not 




If a medication or maternal illness was known to be associated with a congenital 
anomaly subgroup included among the controls, a sensitivity analysis was conducted 
excluding the relevant congenital anomaly subgroup from the controls.  
 
In recognition of  the potential for multiple testing to generate significant results by 
chance, the need to avoid overreliance on significance testing23,24 and the low power of 
analyses of rare exposures, we pre-specified criteria for interpretation of the results. We 
considered a signal from the literature to be ‘supported’ if the aOR ≥1.5 and the CI excluded 
1. If the aOR was ≥1.5 and the CIs did not exclude 1 the signal was ‘weakly supported’.  New 
signals generated in the exploratory analysis were only considered if the aOR was ≥1.5 with 
CI excluding 1. Where the lower 95% CI of a new signal was not ≥1.5, generated signals 
were considered weak.  We did not consider aORs <1.5 for signal evaluation or generation 
due to the small number of gastroschisis cases and the greater potential for confounding.  
 
All medication and maternal illness exposures found to be associated with gastroschisis 
were validated by confirming the gastroschisis diagnosis, medication/illness exposure and 
timing of the exposure with the registries. The ratio of gastroschisis cases isolated/potentially 
multiply malformed was explored for associations with 10 or more exposures to identify any 




Ethical approval was provided by the University of Ulster Nursing Research 






Gastroschisis population  
 
Excluding those with chromosomal/monogenic syndromes there were 1,587 
gastroschisis cases across the 18 EUROmediCAT registries (1995-2012), for a total 
prevalence of 2.0 [95% CI 1.9, 2.1] gastroschisis cases per 10,000 births.  The prevalence of 
gastroschisis varied across the registries (Table 1).  
 
After exclusions, 1,577 gastroschisis cases, 83.0% of which were isolated, were 
compared to 153,357 non-chromosomal/monogenic controls.  Of the gastroschisis cases 85% 
were live births, 4% stillbirths and 11% TOPFAs.  69% of cases were prenatally diagnosed 
(including TOPFA).  Excluding TOPFAs 60% of cases were preterm (<37 gestational weeks) 
and 63% low birthweight (<2500g).  Adjusting for registry and time period, cases were more 
likely to have been born to young mothers [<20, aOR 5.76, 95% CI 4.93, 6.72; 20-24, aOR 
2.76, 95% CI 2.42-3.15] and less likely to have been born to older mothers [30+, aOR 0.44, 
95% CI 0.38-0.53], compared to mothers aged 25-29.   
 
Medication exposures: Signal evaluation 
 
The signal for antidepressants was supported (Table 2).  The majority of antidepressant 
exposures were to selective serotonin reuptake inhibitors (SSRIs) with fluoxetine, citalopram 
and sertraline all associated with gastroschisis (Table 2). After excluding congenital heart 
disease controls due to their putative association with SSRIs,12,25 the OR was essentially 
unchanged (aOR 2.40, 95% CI 1.36, 4.27). Antidepressant, and SSRI exposure, were twice as 
15 
 
prevalent among mothers 30+ years old than among those <20, but there was no evidence of 
an interaction between maternal age and antidepressant exposure in their effect on 
gastroschisis risk (Likelihood-ratio test χ2 (3df) 2.77, P=0.43) or between maternal age and 
SSRI exposure (Likelihood-ratio test χ2 (3df) 1.58, P=0.66).   
 
The signal for oral contraceptives was supported (Table 2) with 8 of the 10 
gastroschisis cases exposed to the combined oral contraceptive levonorgestrel and 
ethinylestradiol.  Exposure to an oral contraceptive was twice as prevalent among mothers 
<20 than among those 30+, but there was no evidence of an interaction between maternal age 
and oral contraceptive exposure (Likelihood-ratio test χ2 (2df) 0.85, P=0.66).   
 
The signal for topical antivirals was supported (Table 2) but there were insufficient 
exposures to test the antiherpetic medication signal. 
 
Signals relating to the analgesics paracetamol, nonsteroidal anti-inflammatory drugs, 
diclofenac, ibuprofen, opioid analgesics and codeine combinations excluding psycholeptics 
were weakly supported (Table 2). There was no support for the aspirin or salicylate 
signals.26,27 
 
There was no support for the signals for asthma medications, either all asthma 
medications, inhaled β2 agonists28, bronchodilators,29 or salbutamol and gastroschisis (Table 
2). Excluding from controls anomalies previously associated with asthma medication28 
produced the same results. 
16 
 
Table 2. The association between Gastroschisis and medications with signals in the literature: number of exposures, number of 








Main Analysis Sensitivity analyses 
Complete dataset Excluding unknown medication 
exposures 
Only medication exposed Excluding diabetes and Anti-Epileptic medication 
exposed 
Crude OR  
[95% CI] 
Adjusted OR  
[95% CI] 
Crude OR  
[95% CI] 
Adjusted OR  
[95% CI] 
Crude OR  
[95% CI] 










Adjusted OR  
[95% CI] 
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It was not possible to test a number of signal medications due to insufficient numbers of exposed gastroschisis cases [n]: dihydrocodeine [n=0], paroxetine [n=0], 
venlafaxine [n=1], antiherpetics [n=2], diphenhydramine [n=0], phenylpropanolamine [n=0], pseudoephedrine [n=0], oral decongestants [n=0].  
a Medication or medication group which is a component of a medication signal and had more than 3, or 3 expected, exposures at the 4th or 5th ATC level 
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Maternal Illness: Signal Evaluation 
 
Cases were less likely than controls to have had maternal exposure to ‘any 
(pregestational or gestational) diabetes’ and pregestational diabetes (Table 3 and Supporting 
Table 4). Excluding from controls anomalies previously associated with diabetes30 somewhat 
decreased the size of the negative association [aOR 0.41, 95% CI 0.17, 0.99 and aOR 0.20, 
95% CI 0.03, 1.45 respectively].  
 
There was weak support for an association with ‘any mental disorder’, depression and 
‘mental and behavioral disorders associated with the puerperium’ (Table 3).  Half of the 
gastroschisis cases with depression and a third of those with ‘mental and behavioral disorders 
associated with the puerperium’ were exposed to an antidepressant in the first trimester. The 
prevalence of these mental disorders varied little across maternal age groups.  
 
Signals for sexually transmitted infections (STIs) excluding and including yeast/vaginal 
infections were supported but there was no evidence for an association with urinary tract 
infection.13,31 STIs including yeast/vaginal infections were six times as prevalent among 
mothers <20 than among mothers 30+ but there was no evidence of an interaction 
(Likelihood-ratio test χ2 (2df) 2.97, P=0.23). The STI diagnosis includes genital herpes but 
there were not enough exposures to genital herpes to explore this exposure directly. 
21 
 
Table 3. The association between Gastroschisis and maternal illness: ICD 9 and ICD 10 code/s, number of exposures in the dataset, 
number of Gastroschisis cases exposed, crude and adjusted ORs 
































 Crude OR [95% 
Confidence Interval] 
Adjusteda OR [95% 
Confidence Interval] 




E10-14, O24 2378 5 0.22 [0.09, 0.52] 0.31 [0.13, 0.75] 
Pregestational diabetesbc 250 E10-14 882 1 0.11 [0.02, 0.82] 0.13 [0.02, 0.92] 
Gestational diabetes c  648.8 O244 1150 4 0.36 [0.14, 0.97] 0.65 [0.24, 1.76] 
Any mental disorder (psychoses, 
neurotic disorders, personality 
disorders, other nonpsychotic mental 
disorders, and mental retardation) 
290-9, 300-3, 
305-9,310-9 
F00-F99 1113 20 1.94 [1.24, 3.04] 1.55 [0.98, 2.44] 
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Depressionc 300.4, 311 F32-3 559 13 2.52 [1.45, 4.39] 2.52 [1.45, 4.39] 
Mental and behavioral disorders 
associated with the puerperium, not 
elsewhere classified 
(postnatal/postpartum depression and 
puerperal psychosis)c  
d F53 41 3 8.32 [2.56, 27.01] 8.32 [2.56, 27.01] 
Urinary tract infection (UTI) 646.6 O23 1211 13 1.14 [0.66, 1.98] 0.95 [0.54, 1.66] 







86 5 6.52 [2.64, 16.13] 2.85 [1.13, 7.24] 
STIs including yeast/vaginal infections 








150 6 4.40 [1.94, 9.99] 2.52 [1.09, 5.85] 
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1298 18 1.49 [0.93, 2.38] 1.17 [0.73, 1.89] 










1355 18 1.42 [0.89, 2.28] 1.13 [0.70, 1.83] 
a Adjusted for maternal age, registry and time period. 
b Analysis includes data from Norway registry. 
c Illness which is a component of an illness signal. 







Medication and maternal illness: Exploratory analyses 
 
Thirty-nine non-signal ATC codes were tested for an association with gastroschisis in 
the exploratory analysis (Supporting Table 3). There were signals for vitamin E [aOR 5.74, 
95% CI 1.68, 19.59, n=3] and bromhexine [aOR 29.48, 95% CI 8.24, 105.50, n=3], and weak 
signals for hydrocortisone [aOR 3.94, 95% CI 1.19, 13.01, n=3] and drotaverine [aOR 2.31, 
95% CI 1.08, 4.97, n=7]. Caution should be used when interpreting the drotaverine and 
vitamin E signals. The drotaverine signal was not robust in the sensitivity analysis and two of 
the three cases involved in the vitamin E signal were also exposed to drotaverine.   
 
Fourteen non-signal maternal illnesses were tested for an association with gastroschisis 
in the exploratory analysis (Supporting Table 4). Further maternal infections were associated 
with gastroschisis, producing a signal for acute tonsillitis [aOR 8.40, 95% CI 2.41, 29.31, 
n=3] and weak signals for ‘acute upper respiratory infections of multiple or unspecified sites’ 
[aOR 2.65, 95% CI 1.46, 4.81, n=13] and ‘bacterial infection of unspecified site’ [aOR 3.56, 
95% CI 1.06, 11.98, n=3]. There were also weak signals for hemorrhage in early pregnancy 
[aOR 1.52, 95% CI 1.01, 2.31, n=27] and ‘gastritis and duodenitis’ [aOR 3.12, 95% CI 1.11, 
8.75, n=4]. 
 
 There was no disproportion in the ratio of isolated to potentially multiply malformed 
gastroschisis cases for any of the medication or maternal illness signals with more than 10 






Gastroschisis is a rare anomaly, occurring on average in one in every 5,000 births in 
Europe. We have added to a growing evidence base that the maternofetal environment is 
important in the causation of gastroschisis, specifically in respect to maternal illness and 
medication, pointing to the need for greater understanding of causal pathways. Among 
teenage mothers, one in every 870 births was affected by gastroschisis, either due to their 
greater vulnerability to, or more frequent exposure to these and other unmeasured factors 
acting singly or in combination. 
 
Mental illness is common among women of reproductive age with an estimated 7-11% 
of pregnant women affected by depression in their first trimester.32  Antidepressants are also 
increasingly being used during pregnancy, with SSRIs the most frequently prescribed.33,34  
Our study confirmed that first trimester exposure to antidepressants, specifically SSRIs,12,25 
and mental disorders,31 including depression, were associated with gastroschisis. As 
antidepressant use is more prevalent among older mothers this relationship is contrary to the 
known association between gastroschisis and young maternal age.  A recent multi-country 
population based cohort study found a low and non-significant OR for SSRIs, particularly 
with sibling controls,35 but was much smaller and did not include stillbirths and TOPFAs. We 
could not effectively control for confounding by indication due to incomplete ascertainment 
of both medication and illness exposures. We had no information on lifestyle factors, such as 
smoking,9 alcohol consumption10 or illicit drug use11 which could confound the association 
with mental health. Whatever the causal pathway, mothers with depression should be 
considered a high-risk group for gastroschisis.  
  
First trimester exposure to oral contraceptives, mainly levonorgestrel and 
ethinylestradiol, was confirmed to be associated with gastroschisis.36 Estrogen related 
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thrombosis has been proposed as one of the pathogenic mechanisms behind gastroschisis.37 
High estrogen levels are typical for young women in the early gestational stages when 
anomalies develop6 and this hormonal mechanism may contribute to the high risk for young 
women. Alternatively, oral contraceptive exposure may be acting as a marker for an 
unplanned pregnancy with a suboptimal periconceptional environment. 
 
Infections repeatedly showed associations with gastroschisis in our data, adding to the 
existing literature.13,31,38  Maternal STI was associated with a 2½-3 times increased risk of 
gastroschisis. Further supporting evidence is provided by studies which found biological 
markers of recent chlamydia infection39 and reactivation of previous herpes simplex virus 
type 2  infection40 to be associated with gastroschisis. STIs may be one of the factors 
explaining the high risk of gastroschisis in young mothers. Both a direct effect and indirect 
effect of STI exposure, through immune and inflammatory responses, have been 
suggested.13,39 While the association found for topical antivirals may be confounded by 
indication there is also the potential for medications used in the treatment of STIs to be 
contributing to the increased risk of gastroschisis. Interestingly, we found no supporting 
evidence for an association with urinary tract infections, contrary to some other studies.13,31  
There was new evidence in our data relating to acute tonsillitis and to a lesser degree 
respiratory infections, bacterial infections, and gastritis/duodenitis (which can be caused by 
helicobacter pylori infection).  Maternal infection as indication may have confounded the 
signals we found for bromhexine, an expectorant, and drotaverine, an antispasmodic.  
 
A number of analgesics were weakly associated with gastroschisis. We found weak 
evidence to support the signal for paracetamol and there is contradictory evidence relating to 
this association in the literature.10,26,41  While we found a weak association with nonsteroidal 
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anti-inflammatory drugs generally, and ibuprofen and diclofenac specifically, both our study 
and another recent study42 found no evidence to support the signals previously published for 
aspirin or salicylates.26,43  There is known under ascertainment for over the counter 
medications in the EUROmediCAT database17 and this will have reduced our power to detect 
an increased risk associated with these analgesics.  If these analgesics were used during 
maternal infections, there is again the potential for confounding by indication.  
 
Pregestational diabetes is a strong risk factor for a range of anomalies.30 The signal for 
an increased risk of gastroschisis in those with (pregestational or gestational) diabetes arose 
in a study with unreliable diabetes ascertainment.44 We found no evidence for an increased 
risk of gastroschisis among those with either any (pregestational or gestational) diabetes or 
pregestational diabetes. Instead, in agreement with another study which was able to control 
for maternal body mass index,31 we found evidence for a protective effect of diabetes. While 
the magnitude of the effect decreased, it persisted after correcting for the fact that our 
malformed controls contained anomalies associated with pregestational diabetes. Further 
evidence to support this apparent protective effect should be sought but it does fit with the 
known negative association between gastroschisis and high maternal body mass index.45   
 
No association was found between asthma medications, either all asthma medications, 
inhaled β2 agonists or bronchodilators, and gastroschisis. This signal arose in a study of 
bronchodilators,29 but previous evidence from EUROmediCAT data has been 
inconsistent.28,46   
 
In a previous study,5 we established that the geographical variation within Europe persisted 
independently of maternal age differences between populations. We have shown here that 
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many of the exposures conferring risk are more common among young mothers. Our ability 
to shed light on the extent to which maternal illness or medication contribute to maternal age 
and geographic variation in prevalence is limited due to incomplete ascertainment of both 
these exposures in cases and controls, and variation in ascertainment between registries. 
Strengths and weaknesses 
 
EUROmediCAT’s international population based database covers a very large 
population suitable for studying a rare condition such as gastroschisis, contains detailed 
coding of all congenital anomalies16 and includes TOPFA which constituted more than 11% 
of gastroschisis cases and 5% of controls.  The data are standardized across the registries, 
although registers differ in their exposure ascertainment methodology.16 Gastroschisis cases 
identified prenatally were confirmed after live/stillbirth.  Practice following TOPFA varies 
but usually either an external or full post-mortem take place. Less than 1% of gastroschisis 
cases occurred in very early TOPFA (before 13 gestational weeks) where diagnostic accuracy 
may be less certain. Although the distinction between gastroschisis and omphalocele was a 
concern in early studies4 the data analysed here started in 1995 when diagnostic accuracy was 
good. Use of the BPA extension to ICD-9 ensured that gastroschisis and omphalocele were 
recorded separately and we excluded all of those with poorly specified abdominal wall 
diagnoses from both cases and controls.  
 
There is no information on confounders such as smoking or alcohol, and limited ability 
to control for confounding by indication. It was therefore not possible to disentangle the 
relative contributions of maternal ill health and the medications used in its treatment.  As 
maternal illness during pregnancy is recorded up to the 20th gestational week acute illnesses, 
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such as infections, may have occurred outside the first trimester, in both cases and controls. 
This will be less of a concern for chronic illnesses such as depression.  
 
Teratogen non-specificity bias, where the exposure in question is associated with both 
cases and controls, may have diluted ORs20. However, when the control group was restricted 
to address this issue the ORs changed very little suggesting that the wide variety of anomalies 
within our control group negated this problem.   
 
There is known under ascertainment of medication exposure in the EUROmediCAT 
database, particularly for over the counter medications.17,47  This will have reduced the power 
of our analysis but should not have introduced bias as cases and controls had equal 
probability of having their exposure recorded.20   
 
Due to multiple testing of many exposures, some chance positive associations are 
likely, but we found more positive associations than expected by chance.  We mitigated this 
by clearly specifying our prior hypotheses, to be tested as signals from the literature, 
examining patterns of exposures (e.g. mental health or infection related) and pre-specifying 




Our study adds strong evidence that antidepressants and/or mental health disorders, a 
variety of maternal infections, particularly STIs, and continuation of oral contraceptives in 
early pregnancy are associated with gastroschisis. Better understanding of these risk factors, 
in particular the complex of risk factors more prevalent among young mothers, who are at 
30 
 
higher risk of gastroschisis, should help target supportive services reducing the prevalence of 
gastroschisis and improving maternal and fetal health more generally. 
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Supporting Appendix 1. Literature Review to Identify ‘Signals’ to be Tested.  
 
Medline, Embase and PubMed were searched, with no date or language limits. For 
medication exposures the search term ‘gastroschisis’ was combined with ‘drug’, 
‘medication’, ‘drug exposure’, ‘drug use’ or ‘prenatal drug exposure’. For maternal illnesses 
‘gastroschisis’ was combined with ‘disease’, ‘acute disease’, ‘chronic disease’, ‘maternal 
disease’, ‘diseases’, ‘maternal illness’, ‘acute illness’ or ‘chronic illness’.  The search was last 
updated on the 13/11/2015.  Only full text articles of original studies exploring the risk of 
gastroschisis in humans were included.  Where “drug” referred to illicit drugs, the 













Adjusted OR [95% 
Confidence 
Intervals] 
Article Country Study Years Design Maternal 
age 
adjustment 
Analgesics Aspirin 13  2.7a [1.2, 5.9] Werler et 

















7  20.4b [2.2, 191.5] Draper et 
al. 2008 2 














7 4.7 [1.2, 18.1]  Torfs et 
al. 1996 3 











Aspirin or ibuprofen 13 5.2 [1.9, 14.6] 4.6c [1.4, 14.7] 
Ibuprofen 6 4.0 [1.0, 16.0]  
  1.6d [1.2, 2.1] Mac Bird 
et al. 
2009 4 









NSAIDs 151  1.4e [1.1, 1.7] Werler et 
al. 2009  5 











Salicylates 5 3.3 [1.1, 9.8] 3.5f No CI provided Martínez-
Frías et 









Paracetamol 120  1.5)a [1.1, 2.2] Werler et 

















Opioid analgesics 26  1.8g [1.1, 2.9] Broussar
d et al. 
2011 7 







Dihydrocodeine 15 3.3 [1.8, 6.1]  
Anti-
depressants 













The Paroxetine 5  2.9i [1.0, 8.4] Alwan et 
al. 2007 9 









13  2.5j [1.2, 4.8] Reefhuis 
et al. 
2015 10 







Venlafaxine 6 3.8 [1.2, 10.5] 5.7k [1.8, 15.9] Polen et 
al. 2013 
11 












4 3.6 [1.1, 11.5] 4.7l [1.2, 19.0] Ahrens et 
al. 2013 
12 









Diphenhydramine 16  2.0m [1.0, 3.9] Gilboa et 
al. 2009 
13 





























17 1.9 [1.1, 3.3] 2.1q [1.2, 3.6] Lin et al. 
2008 15 











Oral contraceptives 40  1.8r [1.3, 2.7] Waller et 
al. 2010 
16 











5 10.0 [1.2, 
85.6] 
 Torfs et 
al. 1996 3 




























35  1.8a [1.0, 3.2] Werler et 



































a Adjusted for education, income, medication use, illness, illicit drug use, and cigarette smoking. Control group consisted of 
both malformed and non-malformed infants 
b Adjusted for use of any recreational drug, use of a vasoactive recreational drug, BMI, marital status, homeowner status, 
history of gynaecologic infection/disease and cigarette smoking. 
c Adjusted for smoking status, prenatal care, mothers father absent during youth, family income and exposure to solvents, 
decongestants, x-rays and ‘cocaine and other drugs’. 
d Adjusted for race/ethnicity, plurality, family income, parity, maternal age, fever, infant sex, any maternal drinking, maternal 
smoking, maternal BMI, gestational diabetes, pre-existing diabetes, folic acid supplementation, study centre and exposure 
to pseudoephedrine, aspirin, paracetamol, naproxen, marijuana, and cocaine 
e Adjusted for maternal age at delivery and state of residence by stratification and for race/ethnicity, BMI, education, alcohol 
use, oral contraceptive use, folic acid supplementation 
f Adjusted for maternal age and smoking status 
g Adjusted for maternal age, race/ethnicity, education, presence or absence of pre-pregnancy obesity, presence or absence of 
periconceptional smoking, and study centre 
h Adjusted for area, maternal age, alcohol, tobacco, illicit drug use, pregestational/gestational diabetes and folic acid 
i Adjusted for maternal race or ethnic group, maternal obesity, maternal smoking and family income. Infants whose mothers 
had pregestational diabetes mellitus type 1 or 2 were excluded 
j Adjusted for maternal race/ethnicity, maternal education, obesity, and smoking 
k Adjusted for maternal age and race/ethnicity 
l Adjusted for maternal age at delivery and BMI before conception 
m Adjusted for maternal age, maternal race or ethnicity, maternal education, entry into prenatal care, parity, household 
income, and study centre, periconceptional folic acid use, smoking, and alcohol intake 
n Includes all medications starting with the ATC code R03. Note this dataset overlaps to some extent with that used in this 
study 
o Adjusted for registry and maternal age 
p Adjusted for registry, maternal age and use of corticosteroids 
q Adjusted for maternal age, ethnicity, educational level, smoking, folic acid, and any of the following vasoactive medications: 
aspirin, ibuprofen, acetaminophen, amoxicillin, pseudoephedrine, phenylpropanolamine, and 
methylenedioxymethamphetamine 
r Adjusted for maternal age 
s Adjusted for maternal age, years of education, parity, alcohol consumption, influenza in the first trimester, interview year, 
study centre and exposure to salicylates, paracetamol, ibuprofen, phenylpropanolamine, other oral decongestants, other 
nasal/ophthalmic decongestants, antihistamines, antibiotics and oral contraceptives 
t Adjusted for maternal age, pre-pregnancy weight, educational level, and smoking 
u Includes all medications starting with the ATC code R03 
v Note this dataset overlaps to some extent with that used in this study 
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Supporting Table 2. Maternal illnesses associated with gastroschisis in the literature, crude, and adjusted ORs and study details 
Maternal 
illness  
Maternal disease Exposed 
cases 
Crude OR [95% 
Confidence 
Intervals] 
Adjusted OR [95% 
Confidence Intervals] 
Article Country  Study Years Design Maternal 
age 
adjustment 




3.16 [1.38, 7.26] 3.20b [1.38, 7.42] Lam et al. 
1999  19 










Diabetes Any (pregestational or 
gestational) diabetes 
19 2.34 [1.39, 3.98] 2.81c [1.42, 5.57] Skarsgard 



















and other endocrine 
dysfunction.) 
6 1.5 [0.7, 3.4] 3.2 for those 20-24d 
[1.2, 8.5] 
Baer et al. 
2015 20 


















disorders, and mental 
retardation) 
75 1.8 [1.4, 2.3] 2.1 for those >24e [1.4, 
3.2] 
Baer et al. 
2015 20 














Previous pregnancy lossa   2.34f (malformed 
controls) [1.37, 3.97] 
3.43 (non-malformed 
controls) [2.07, 5.66] 
Rittler et 
















Infection Chest cold 5 16.8 [1.98, 150.3]  Elliott et 
al. 2009 22 










Sore throat 5 12.7 [1.3, 122.5]  
Viral infection 
‘complicating pregnancy’ 
40 1.8 [1.3, 2.5] 2.0 for those 20-
24g[1.3, 3.3] 
 
2.1 for those >24h [1.3, 
3.6] 
Baer et al. 
2015 20 











Other specified infection 
complicating pregnancy 
(including tuberculosis, 
malaria, rubella, and 
other specified 
infectious and parasitic 
diseases) 
17 1.9 [1.2, 3.1] 2.0 for those 20-24i 
[1.0, 3.8] 
Baer et al. 
2015  20 











UTI 60 1.9 [1.5, 2.6] 1.4j [1.0, 2.0] Feldkamp 
et al. 2008 
23 
 






UTI  127 1.9 [1.6, 2.3] 1.5 for those <20k [1.1, 
1.9] 
Baer et al. 
2015 20 











UTI 33 3.6 [2.5, 5.4] 2.3l [1.5, 3.5] Yazdy et 










Genital herpes (including 
those with use of 
Antiherpetic medication) 
6 3.2 [1.3, 8.1] 4.7m [1.7, 13.3] Ahrens et 
al. 2013 12 







(excluding those with 
use of Antiherpetic 
medication) 
16 2.6 [1.5, 4.6] 3.0m [1.6, 5.7] 
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STI 17 2.7 [1.7, 4.4] 2.0 for those <20n 
[1.1, 3.6] 
Baer et al. 
2015 20 











STI 14 1.7 [1.0, 3.0] 1.3h [0.7, 2.3] Feldkamp 
et al. 2008 
23 
 








33 1.3 [1.1, 1.6] 1.2j [1.0, 1.5] Yazdy et 










UTI or STI 81 2.0 [1.6, 2.6] 1.5h [1.1, 1.9] Feldkamp 
et al. 2008 
23 
 






UTI or STI including 
yeast/vaginal infections 
73 2.4 [1.8, 3.1] 1.8j [1.3, 2.4] Yazdy et 










UTI & STI 7 6.8 [2.6, 17.5] 4.0h [1.4, 11.6] Feldkamp 
et al. 2008 
23 
 




2003           
Case-control Yes 
UTI & STI including 
yeast/vaginal infections 
7 1.5 [1.1, 1.9] 1.2j [0.9, 1.6] Yazdy et 










Prior history of 
gynaecologic infection or 
disease (recurrent UTI, 
chlamydia or abnormal 
smear prior to current 
pregnancy)a 
18 2.8 [1.4, 5.5] 2.6o [1.2, 5.6] Draper et 
al. 2008  2 















a Not considered a maternal illness within the EUROCAT illness variable and therefore not analysed. 
b Adjusted for maternal age and ethnicity 
c Adjusted for area, maternal age, alcohol, tobacco, illicit drug use, depression medication and folic acid 
d Adjusted for race/ethnicity, type of health insurance, education, parity, mother’s country of birth, obesity, any diabetes, any 
gestational hypertension, viral infection and other specified infection 
e Adjusted for race/ethnicity, type of health insurance, education, parity, obesity, smoking, any gestational hypertension and 
viral infection 
f Adjusted for hospital, year of birth, young paternal age, maternal education, paternal education, paternal occupation, 
consanguinity, race/ethnicity, short inter-birth interval, change in paternity, parity, duration of cohabitation, prenatal 
control, medication, maternal illness, smoking, alcohol and illicit drugs 
g Adjusted for adjusted for race/ethnicity, type of health insurance, education, parity, mothers country of birth, obesity, any 
diabetes, any gestational hypertension, other specified infection and other endocrine disorder 
h Adjusted for race/ethnicity, type of health insurance, education, parity, obesity, smoking, any gestational hypertension and 
mental disorder 
i Adjusted for race/ethnicity, type of health insurance, education, parity, mother’s country of birth, obesity, any diabetes, any 
gestational hypertension, viral infection and other endocrine disorder 
j Adjusted for maternal age, BMI before conception, smoking, and Hispanic ethnicity 
k Adjusted for adjusted for race/ethnicity, obesity, smoking, any gestational hypertension, sexually transmitted infection and 
drug dependency 
l   Adjusted for maternal age 
m   Adjusted for maternal age at delivery and BMI before conception 
n Adjusted for race/ethnicity, obesity, smoking, any gestational hypertension, urinary tract infection and drug dependency 
o Adjusted for use of any recreational drug, use of a vasoactive recreational drug, use of aspirin, BMI, marital status, 
homeowner status and cigarette smoking 




Supporting Table 3. Medication exploratory analysis results - crude and maternal age, registry and time adjusted ORs for main and sensitivity analyses 
Medication/medication 
group  
Main analysis Sensitivity analyses 
Complete dataset 
Excluding unknown drug 
exposures 











































































































































































aluminium, calcium and 
magnesium compounds 
339 1 0.3 [0.0, 2.1] 0.6 [0.1, 4.6] 0.3 [0.0, 1.9] 0.6 [0.1, 4.0] 0.3 [0.0, 1.9] 0.4 [0.1, 2.7] 329 1 0.3 [0.0, 2.1] 0.6 [0.1, 4.6] 
Metoclopramide 409 3 0.7 [0.2, 2.3] 0.6 [0.2, 2.0] 0.7 [0.2, 2.0] 0.7 [0.2, 2.2] 0.7 [0.2, 2.1] 0.6 [0.2, 2.0] 404 3 0.7 [0.2, 2.3] 0.7 [0.2, 2.1] 
Drotaverine 249 7 2.8 [1.3, 6.0] 2.3 [1.1, 5.0] 2.6 [1.2, 5.4] 2.4 [1.1, 5.2] 2.7 [1.3, 5.8] 1.8 [0.8, 3.9] 245 7 2.9 [1.3, 6.1] 2.3 [1.1, 5.0] 
Propulsives 442 3 0.7 [0.2, 2.1] 0.6 [0.2, 1.9] 0.6 [0.2, 1.9] 0.6 [0.2, 2.1] 0.6 [0.2, 1.9] 0.6 [0.2, 1.9] 436 3 0.7 [0.2, 2.1] 0.6 [0.2, 2.0] 
Insulins and analogues 
for injection, fast-acting 
312 2 0.6 [0.2, 2.5] 0.6 [0.2, 2.4] 0.6 [0.1, 2.3] 0.5 [0.1, 2.2] 0.6 [0.1, 2.4] 0.6 [0.1, 2.3] 









18 1.0 [0.7, 1.7] 1.0 [0.7, 1.7] 









16 1.0 [0.6, 1.6] 1.0 [0.6, 1.6] 




6.8 [2.1, 22] 6.0 [1.7, 21.5] 
  




Magnesium 552 9 1.6 [0.8, 3.2] 1.4 [0.6, 3.0] 1.5 [0.8, 2.8] 1.4 [0.6, 3.0] 
  
512 9 1.7 [0.9, 3.4] 1.4 [0.6, 3.0] 
Enoxaparin 227 3 1.3 [0.4, 4.1] 1.6 [0.5, 5.2] 1.2 [0.4, 3.7] 1.4 [0.4, 4.3] 1.2 [0.4, 3.9] 1.6 [0.5, 5.2] 214 3 1.4 [0.4, 4.3] 1.8 [0.6, 5.5] 
Iron bivalent, oral 
preparations 




12 1.0 [0.6, 1.8] 1.2 [0.6, 2.1] 
Ferrous sulphate 834 11 1.3 [0.7, 2.4] 1.5 [0.8, 2.7] 1.2 [0.7, 2.1] 1.1 [0.6, 2.0] 
  
808 11 1.3 [0.7, 2.4] 1.5 [0.8, 2.8] 
Folic acid 9,98
1 




97 1.0 [0.8, 1.2] 0.9 [0.7, 1.1] 
Gynecological 
antibiotics 
234 3 1.3 [0.4, 4.0] 1.5 [0.5, 4.9] 1.1 [0.4, 3.6] 1.1 [0.3, 3.6] 1.2 [0.4, 3.7] 1.2 [0.4, 3.9] 219 3 1.3 [0.4, 4.2] 1.6 [0.5, 5.1] 
48 
 
Imidazole derivatives 377 3 0.8 [0.3, 2.5] 1.0 [0.3, 3.1] 0.7 [0.2, 2.2] 0.9 [0.3, 2.9] 0.7 [0.2, 2.3] 0.7 [0.2, 2.2] 366 3 0.8 [0.3, 2.5] 1.0 [0.3, 3.1] 
Isoxsuprine 
hydrochloride 
494 1 0.2  [0.0, 1.4] 0.5 [0.1, 3.8] 0.2 [0.0, 1.3] 0.4 [0.1, 3.1] 0.2 [0.0, 1.3] 0.3 [0.0, 1.9] 486 1 0.2 [0.0, 1.4] 0.5 [0.1, 3.8] 
Pregnen (4) derivatives 1,31
5 
7 0.5 [0.3, 1.1] 0.8 [0.4, 1.7] 0.5 [0.2, 1.0] 0.8 [0.4, 1.7] 0.5 [0.2, 1.0] 0.7 [0.3, 1.4] 1,26
0 
7 0.5 [0.3, 1.1] 0.8 [0.4, 1.8] 
Progesterone 1,16
0 
6 0.5 [0.2, 1.1] 0.8 [0.4, 1.8] 0.5 [0.2, 1.0] 0.8 [0.3, 1.7] 0.5 [0.2, 1.0] 0.7 [0.3, 1.5] 1,11
3 
6 0.5 [0.2, 1.2] 0.8 [0.4, 1.8] 
Dydrogesterone 732 10 1.4  [0.7, 2.5] 1.6 [0.8, 3.0] 1.2 [0.7, 2.3] 1.7 [0.9, 3.2] 1.3 [0.7, 2.4] 1.2 [0.6, 2.3] 722 10 1.4 [0.7, 2.5] 1.6 [0.9, 3.0] 
Glucocorticoids 565 2 0.4 [0.1, 1.4] 0.6 [0.1, 2.3] 0.3 [0.1, 1.3] 0.4 [0.1, 1.6] 0.3 [0.1, 1.3] 0.4 [0.1, 1.6] 525 2 0.4 [0.1, 1.5] 0.6 [0.2, 2.4] 
Levothyroxine sodium 1,30
1 
7 0.5 [0.3, 1.1] 0.9 [0.4, 1.9] 0.5 [0.2, 1.0] 0.8 [0.4, 1.7] 0.5 [0.2, 1.0] 0.8 [0.4, 1.7] 1,17
9 
7 0.6 [0.3, 1.2] 1.0 [0.5, 2.1] 
Amoxicillin and 
clavulanic acid 





18 1.3 [0.8, 2.1] 1.3 [0.8, 2.1] 1.2 [0.7, 1.8] 1.2 [0.8, 2.0] 1.2 [0.7, 2.0] 1.1 [0.7, 1.8] 1,36
0 
17 1.2 [0.8, 2.0] 1.2 [0.8, 2.0] 
Amoxicillin 816 8 1.0 [0.5, 2.0] 1.0 [0.5, 2.1] 0.9 [0.4, 1.8] 1.0 [0.5, 2.0] 0.9 [0.4, 1.8] 0.8 [0.4, 1.6] 799 8 1.0 [0.5, 2.0] 1.0 [0.5, 2.1] 
Pivmecillinam 389 9 2.3 [1.2, 4.5] 1.7 [0.8, 3.3] 2.1 [1.1, 4.1] 2.0 [0.9, 4.2] 2.2 [1.1, 4.4] 1.9 [0.9, 3.7] 376 8 2.1 [1.0, 4.3] 1.5 [0.7, 3.2] 
Beta-lactamase 
sensitive penicillins 
339 7 2.1 [1.0, 4.4] 1.8 [0.8, 3.8] 1.9 [0.9, 3.9] 1.9 [0.8, 4.1] 2.0 [0.9, 4.2] 1.8 [0.8, 3.9] 328 7 2.1 [1.0, 4.5] 1.9 [0.9, 4.0] 
Phenoxymethyl-
penicillin 




377 3 0.8 [0.3, 2.5] 1.0 [0.3, 3.2] 0.7 [0.2, 2.2] 0.9 [0.3, 2.9] 0.7 [0.2, 2.3] 0.7 [0.2, 2.2] 362 3 0.8 [0.3, 2.5] 1.0 [0.3, 3.3] 
Macrolides 456 1 0.2 [0.0, 1.5] 0.3 [0.0, 1.8] 0.2 [0.0, 1.4] 0.2 [0.0, 1.6] 0.2 [0.0, 1.4] 0.2 [0.0, 1.5] 441 1 0.2 [0.0, 1.6] 0.3 [0.0, 1.8] 
Nitrofurantoin 219 4 1.8 [0.7, 4.9] 1.7 [0.6, 4.7] 1.6 [0.6, 4.4] 1.8 [0.6, 4.9] 1.7 [0.6, 4.7] 1.4 [0.5, 3.9] 212 4 1.9 [0.7, 5.0] 1.7 [0.6, 4.8] 
Valproate 263 4 1.5 [0.6, 4.1] 1.5 [0.5, 3.9] 1.4 [0.5, 3.7] 1.4 [0.5, 3.8] 1.4 [0.5, 3.8] 1.1 [0.4, 3.0] 
    
‘Other’ antiepileptics 188 3 1.6 [0.5, 5.0] 1.2 [0.4, 3.9] 1.4 [0.5, 4.5] 1.1 [0.4, 3.6] 1.5 [0.5, 4.7] 1.1 [0.3, 3.4] 
    
Benzodiazepine 
derivatives 
394 5 1.3 [0.5, 3.1] 1.6 [0.7, 4.0] 1.1 [0.5, 2.7] 1.6 [0.7, 4.0] 1.2 [0.5, 2.9] 1.3 [0.5, 3.2] 349 5 1.4 [0.6, 3.4] 1.8 [0.7, 4.3] 
Diazepam 195 3 1.5 [0.5, 4.8] 1.5 [0.5, 4.8] 1.4 [0.4, 4.3] 1.6 [0.5, 5.0] 1.4 [0.5, 4.5] 1.3 [0.4, 4.0] 175 3 1.7 [0.5, 5.3] 1.6 [0.5, 5.1] 
Nasal corticosteroids for 
topical use 
255 3 1.2 [0.4, 3.6] 1.4 [0.4, 4.5] 1.1 [0.3, 3.3] 1.4 [0.4, 4.5] 1.1 [0.4, 3.4] 1.4 [0.4, 4.4] 244 3 1.2 [0.4, 3.8] 1.5 [0.5, 4.7] 
Betamethasone 351 2 0.6 [0.1, 2.3] 0.9 [0.2, 3.5] 0.5 [0.1, 2.0] 0.6 [0.1, 2.3] 0.5 [0.1, 2.1] 0.6 [0.2, 2.4] 324 2 0.6 [0.2, 2.4] 0.9 [0.2, 3.7] 






















Supporting Table 4. Maternal illness signal analysis results - crude and maternal age, registry and time adjusted ORs 
 





Crude OR [95% CI] Adjusted OR [95% CI] 
All pregestational Diabetes Mellitusa  250 E10-14 882 1 0.1 [0.0, 0.8] 0.1 [0.0, 0.9] 
All Diabetes Mellitus (pregestational and 
gestational)  
250, 648.0, 648.8 E10-14, O24 2378 5 0.2 [0.1, 0.5] 0.3 [0.1, 0.8] 
Gestational Diabetes Mellitus 648.8 O244 1150 4 0.4 [0.1, 1.0] 0.7 [0.2, 1.8] 
Other Endocrine disorders  251-9 E15,E16, E2, 
E30-5,  
223 1   
Mental Disorder 290-9, 300-3, 
305-9,310-9 
F00-F99 1113 20 1.9 [1.2, 3.0] 1.6 [1.0, 2.4] 
Depression 300.4, 311 F32-3 559 13 2.5 [1.5, 4.4] 2.5 [1.5, 4.4] 
Mental and behavioural disorders associated 
with the puerperium  
 
F53 41 3 8.3 [2.6, 27.0] 8.3 [2.6, 27.0] 
Chest Cold  466 J20, J21 41 0 
  
Sore Throat  462, 472.1 J02, J31.2 90 1 
  









056   
 
8 0   
Urinary Tract Infection (UTI) 646.6 O23 1211 13 1.1 [0.7, 2.0] 1.0 [0.5, 1.7] 
Genital Herpes 054.1 A60.0 2 0   
Genital Herpes - excluding those taking 
antiherpetic medication 
054.1 A60.0 2 0   





86 5 6.5 [2.6, 16.1] 2.9 [1.1, 7.2] 






150 6 4.4 [1.9, 10.0] 2.5 [1.1, 5.9] 






1298 18 1.5 [0.9, 2.4] 1.2 [0.7, 1.9] 
51 
 






1355 18 1.4 [0.9, 2.3] 1.1 [0.7, 1.8] 






1 0   












Supporting Table 5. Maternal illness exploratory analysis results - crude and maternal age, registry and time adjusted ORs  
 




Crude OR [95% 
CI] 
Adjusted OR [95% 
CI] 
Asthmaa 493 J45 21,166 31 1.5 [1.1, 2.2] 1.1 [0.8, 1.6] 
Epilepsya 345 G40 974 7 1.1 [0.5, 2.3] 1.0 [0.5, 2.1] 
Pre-eclampsiaa 642.5 O14 817 5 0.6 [0.3, 1.5] 0.5 [0.2, 1.2] 
Gastritis and duodenitis 535 K29 101 4 4.4 [1.6, 11.9[ 3.1 [1.1, 8.8] 





1010 2 0.2 [0.1, 0.8] 0.3 [0.1, 1.2] 
Obesity 278 E66 1555 12 0.8 [0.5, 1.4] 0.6 [0.3, 1.0] 
Haemorrhage in early pregnancy 640 O20 2028 27 1.4 [1.0, 2.1] 1.5 [1.0, 2.3] 
Acute upper respiratory infections of multiple or unspecified 
sites 
465 J06 360 13 4.0 [2.3, 7.0] 2.7 [1.5, 4.8] 
Premature rupture of the membranes 658.1 O42 276 5 1.9 [0.8, 4.7] 1.2 [0.4, 3.3] 
Influenza 487, 
488 
J09-J11 705 3 0.5 [0.1, 1.4] 0.9 [0.3, 2.9] 
Bacterial Infection of Unspecified Site b A49 47 3 7.2 [2.2, 23.2] 3.6 [1.1, 12.0] 
Hyperemesis 643 O21 371 4 1.2 [0.4, 3.1] 1.0 [0.4, 2.7] 
Tonsillitis 463 J03 37 3 9.3 [2.9, 30.3] 8.4 [2.4, 29.3] 
a Includes Norway registry 
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Supporting Figure 1. Flowchart detailing number of congenital anomaly affected foetuses, 




A includes those with pregestational diabetes, gestational diabetes or exposure to an 
antidiabetic medication.  
B includes only those exposed to a medication, exposed only to vitamin/minerals, or known 
not to be exposed to a medication.  




Supporting figure 2. Flowchart detailing the literature review for first trimester medication 
exposure signals.  
 
 
Records identified through database 
searching  
(n = 183) 
Additional records identified 
through other sources  
(n = 4) 
Records after duplicates removed  
(n = 138) 
Records screened  
(n = 138) 
Records excluded  
(n = 57) 
Full-text articles assessed 
for drug exposure risk 
factors  
(n = 81) 
Full-text articles excluded- 
no drug exposure risk 
factors identified or 
review of other studies 
(n = 63) 
Original studies identifying 
medication exposure 
signals  
(n = 18) 
Medication/medication 
group signals identified 
(included in analysis)  
(n = 20) 
Illicit drug/drug group 
signals identified 
(Not included in analysis) 
(n = 5) 
57 
 
Supporting figure 3. Flowchart detailing the literature review for first trimester maternal 
illness exposure signals 
 
Records identified through database 
searching  
(n = 176) 
Additional records identified through 
other sources  
(n = 5) 
Records after duplicates removed  
(n = 181) 
Records screened  
(n = 181) 
Records excluded  
(n = 141) 
Full-text articles assessed for 
drug exposure risk factors  
(n = 40) 
Full-text articles excluded  
(n = 31) 
Original studies identifying 
maternal illness risk factors  
(n = 9) 
Individual/group of maternal 
illness diagnoses signals 
(included in analysis)  
(n = 16) 
Individual/group of maternal 
illness diagnoses signals (not 
included in analysis)  
(n = 3) 
